11/5/2009

The FDA gave Shire's velaglucerase alfa priority-review status as a treatment for Gaucher disease and a potential alternative to Genzyme's Cerezyme, which is in limited supply. The agency is expected to hand down its approval decision by Feb 28.

Related Summaries